Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) EBIT: 2022-2025

Historic EBIT for ARS Pharmaceuticals (SPRY) over the last 4 years, with Sep 2025 value amounting to -$53.2 million.

  • ARS Pharmaceuticals' EBIT fell 144.58% to -$53.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$90.8 million, marking a year-over-year decrease of 50.04%. This contributed to the annual value of -$3.1 million for FY2024, which is 95.43% up from last year.
  • As of Q3 2025, ARS Pharmaceuticals' EBIT stood at -$53.2 million, which was down 11.72% from -$47.6 million recorded in Q2 2025.
  • ARS Pharmaceuticals' 5-year EBIT high stood at $47.2 million for Q4 2024, and its period low was -$53.2 million during Q3 2025.
  • For the 3-year period, ARS Pharmaceuticals' EBIT averaged around -$19.0 million, with its median value being -$18.7 million (2023).
  • Per our database at Business Quant, ARS Pharmaceuticals' EBIT crashed by 224.76% in 2023 and then skyrocketed by 561.54% in 2024.
  • Over the past 4 years, ARS Pharmaceuticals' EBIT (Quarterly) stood at -$15.4 million in 2022, then surged by 33.78% to -$10.2 million in 2023, then spiked by 561.54% to $47.2 million in 2024, then crashed by 144.58% to -$53.2 million in 2025.
  • Its EBIT was -$53.2 million in Q3 2025, compared to -$47.6 million in Q2 2025 and -$37.2 million in Q1 2025.